Stock Option Plan (Tables) - Blade Therapeutics, Inc. [Member]

12 Months Ended

Dec. 31, 2021

Stock Option Plan (Tables) [Line Items]

Schedule of stock option plan exercised option

					Weighted Average
	Shares Available for Grant		Number of Options Outstanding		Exercise Price		Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2019	4,032,081		14,028,646		$	0.26	8.85	$	1,197
Shares authorized	5,000,000		—
Granted	(5,957,116	)	5,957,116			0.47
Exercised	—		(473,594	)		0.21
Forfeited	2,043,185		(2,043,185	)		0.32
Repurchased	33,691		—			0.14
Outstanding at December 31, 2020	5,151,841		17,468,983		$	0.33	7.76	$	2,794
Shares authorized	4,200,000
Granted	(7,980,914	)	7,980,914			0.51
Exercised	—		(2,147,445	)		0.23
Forfeited	1,749,610		(1,749,610	)		0.31
Outstanding at December 31, 2021	3,120,537		21,552,842		$	0.41	7.51	$	3,073
Exercisable at December 31, 2021			9,000,500		$	0.33	5.56	$	2,008

Schedule of grant-date fair values of employee and non-employee stock options

	Year Ended December 31,
	2020	2021
Risk-free interest rate	0.35% – 1.42%	0.64% – 1.13%
Weighted-average expected term (years)	5.93 – 6.07	5.85 – 6.08
Expected dividends	—%	—%
Weighted-average expected volatility	80.54% – 84.21%	79.34% – 83.46%

Schedule of stock-based compensation expense

	Year Ended December 31,
	2020		2021
	(in thousands)
Research and development	$	511	$	377
General and administrative		394		1,019
Total stock-based compensation expense	$	905	$	1,396